Provided by Tiger Trade Technology Pte. Ltd.

Werewolf Therapeutics, Inc.

0.4530
-0.0030-0.66%
Volume:173.82K
Turnover:77.97K
Market Cap:21.99M
PE:-0.37
High:0.4683
Open:0.4500
Low:0.4400
Close:0.4560
52wk High:2.38
52wk Low:0.4040
Shares:48.54M
Float Shares:35.00M
Volume Ratio:0.69
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2354
EPS(LYR):-1.3300
ROE:-161.89%
ROA:-42.33%
PB:1.80
PE(LYR):-0.34

Loading ...

Company Profile

Company Name:
Werewolf Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
39
Office Location:
200 Talcott Ave,2nd Floor,Watertown,Massachusetts,United States
Zip Code:
02472
Fax:
- -
Introduction:
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Daniel J. Hicklin
Director,President and Chief Executive Officer
Luke Evnin
Chairman of the Board and Independent Director
Anil Singhal
Independent Director
Meeta Chatterjee
Independent Director
Michael B. Atkins
Independent Director
Michael Sherman
Independent Director
Briggs Morrison
Director

Shareholders

Name
Position
Daniel J. Hicklin
Director,President and Chief Executive Officer
Michael Urban
Principal Financial Officer and Principal Accounting Officer
Steven Bloom
Chief Business Officer